Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||MTIG7192A + RO7247669|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|MTIG7192A||RO7092284|RG6058|Tiragolumab||Immune Checkpoint Inhibitor 136 TIGIT Antibody 10||Tiragolumab (MTIG7192A) is an anti-human TIGIT (T cell immunoreceptor with Ig ITIM domain) antibody that potentially has anti-tumor activities through modulating the immune response to tumors (PMID: 29991503, PMID: 32576590).|
|RO7247669||RO-7247669|RO 7247669||LAG3 Antibody 15 PD-L1/PD-1 antibody 80||RO7247669 is a bispecific antibody that targets both PD-1 (PDCD1; CD279) and the lymphocyte activation gene 3 protein (LAG3), potentially resulting in decreased inhibition of T-cell activation and proliferation, and increased anti-tumor cytotoxic T-lymphocyte response (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT05116202||Phase Ib/II||RO7247669 Atezolizumab + MTIG7192A Ipilimumab + Nivolumab MTIG7192A + RO7247669||A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma)||Recruiting||USA||2|